OBJECTIVE: To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations. METHODS: This 48-week, multicenter, open-label clinical trial randomized patients to TDM versus standard of care (SOC). Serial pharmacokinetics, including a week-2 3-sample sparse collection, and expert committee TDM recommendations were given to TDM-arm patients' providers. RESULTS:Seventy-four (39%) of 190 patients had week-2 concentrations outside of targets and 122 (64%) of 190 had nontarget exposure at least once over 48 weeks. Providers accepted 75% of TDM recommendations. Among patients with below-target concentrations, more TDM-arm than SOC-arm patients achieved targets (65% vs. 45%; P = 0.09). Increased body weight and efavirenz or lopinavir/ritonavir use were significant predictors of nontarget concentrations. Patients at target and patients who achieved targets after TDM-directed dose modifications trended toward greater viral load reductions at week 48 than patients with below-target exposures (HIV RNA reductions: 2.4, 2.3, and 1.9 log10 copies/mL, respectively; P = 0.09). CONCLUSIONS: Most patients had nontarget PI and/or NNRTI concentrations over 48 weeks. TDM recommendations were well accepted and improved exposure. Patients below TDM targets trended toward worse virologic response.
RCT Entities:
OBJECTIVE: To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations. METHODS: This 48-week, multicenter, open-label clinical trial randomized patients to TDM versus standard of care (SOC). Serial pharmacokinetics, including a week-2 3-sample sparse collection, and expert committee TDM recommendations were given to TDM-arm patients' providers. RESULTS: Seventy-four (39%) of 190 patients had week-2 concentrations outside of targets and 122 (64%) of 190 had nontarget exposure at least once over 48 weeks. Providers accepted 75% of TDM recommendations. Among patients with below-target concentrations, more TDM-arm than SOC-arm patients achieved targets (65% vs. 45%; P = 0.09). Increased body weight and efavirenz or lopinavir/ritonavir use were significant predictors of nontarget concentrations. Patients at target and patients who achieved targets after TDM-directed dose modifications trended toward greater viral load reductions at week 48 than patients with below-target exposures (HIV RNA reductions: 2.4, 2.3, and 1.9 log10 copies/mL, respectively; P = 0.09). CONCLUSIONS: Most patients had nontarget PI and/or NNRTI concentrations over 48 weeks. TDM recommendations were well accepted and improved exposure. Patients below TDM targets trended toward worse virologic response.
Authors: Brookie M Best; Peter P Koopmans; Scott L Letendre; Edmund V Capparelli; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Gilbert Mbeo; J Allen McCutchan; David M Simpson; Richard Haubrich; Ronald Ellis; Igor Grant Journal: J Antimicrob Chemother Date: 2010-11-23 Impact factor: 5.790
Authors: Robin DiFrancesco; Susan Rosenkranz; A Lisa Mukherjee; Lisa M Demeter; Hongyu Jiang; Robert DiCenzo; Carrie Dykes; Alex Rinehart; Mary Albrecht; Gene D Morse Journal: Ther Drug Monit Date: 2010-08 Impact factor: 3.681
Authors: Ighovwerha Ofotokun; Jeffrey L Lennox; Molly E Eaton; James C Ritchie; Kirk A Easley; Svetlana E Masalovich; Mary C Long; Edward P Acosta Journal: J Clin Pharmacol Date: 2011-01-05 Impact factor: 3.126
Authors: José Moltó; Manuel José Barbanoj; Cristina Miranda; Asunción Blanco; José Ramón Santos; Eugenia Negredo; Joan Costa; Pere Domingo; Bonaventura Clotet; Marta Valle Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447
Authors: Lisa M Demeter; Hongyu Jiang; A Lisa Mukherjee; Gene D Morse; Robin DiFrancesco; Robert DiCenzo; Carrie Dykes; Prakash Sista; Lee Bacheler; Karin Klingman; Alex Rinehart; Mary Albrecht Journal: AIDS Date: 2009-01-28 Impact factor: 4.177